Glucocorticoid-induced osteoporosis is the most common secondary form of the disorder and up to 50% of patients receiving long-term therapy will suffer an osteoporotic fracture. Bone mineral density (BMD) decreases by 6-12% during the first year of administration of glucocorticoids but the relative risk of fracture increases more rapidly, escalating by as much as 75% within the first three months of treatment, suggesting that the adverse effects of glucocorticoid excess on bone are due to abnormalities seemingly separate from the decline in BMD. Indeed, it is clear that BMD is only one of several factors contributing to bone strength. Bone size, architecture and material properties make separate contributions. In this application, it is proposed that part of the adverse skeletal impact of glucocorticoid excess is due to an increase in the prevalence of osteocyte apoptosis and that osteocyte apoptosis negatively affects bone strength by degrading bone material properties, by allowing accumulation of damaged bone, or both. To advance this hypothesis, it is proposed to: (1) Establish the contributions of glucocorticoid-induced osteocyte apoptosis to bone strength by overexpressing 11b-hydroxysteroid dehydrogenase 2 (11b-HSD2), an enzyme that inactivates glucocorticoids before they reach the glucocorticoid receptor, in osteoblasts and osteocytes of transgenic mice by using the osteocalcin promoter and thereby protecting these cells from glucocorticoid-induced apoptosis. Determine how strength is maintained in spite of loss of BMD or changes in cancellous and cortical microarchitecture; (2) Overexpress 11b-HSD2 under control of the tartrate-resistant acid phosphatase promoter to guard osteoclasts in transgenic mice from glucocorticoid exposure thus preventing the glucocorticoid-induced early loss of bone and creating the opportunity to determine if osteocyte apoptosis and loss of bone strength occur nonetheless; (3) Rapidly ablate osteocytes and mature osteoblasts with diphtheria toxin by using transgenic mice expressing the diphtheria toxin receptor under control of the osteocalcin promoter to determine if bone strength is decreased before BMD and microarchitecture are altered. The proposed research plan will reveal the role of osteocyte survival in bone strength and how osteocytes achieve this objective. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
2R01AR046191-06
Application #
6827876
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Sharrock, William J
Project Start
1999-09-15
Project End
2006-08-31
Budget Start
2004-09-01
Budget End
2005-08-31
Support Year
6
Fiscal Year
2004
Total Cost
$306,061
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Jilka, Robert L; O'Brien, Charles A; Ali, A Afshan et al. (2009) Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone 44:275-86
Boskey, A L; Spevak, L; Weinstein, R S (2009) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20:793-800
Ali, A Afshan; Weinstein, Robert S; Stewart, Scott A et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146:1226-35
O'Brien, Charles A; Jilka, Robert L; Fu, Qiang et al. (2005) IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 289:E784-93
O'Brien, Charles A; Jia, Dan; Plotkin, Lilian I et al. (2004) Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145:1835-41
Weinstein, Robert S; Jia, Dan; Powers, Cara C et al. (2004) The skeletal effects of glucocorticoid excess override those of orchidectomy in mice. Endocrinology 145:1980-7
Combs, Terry P; Berg, Anders H; Rajala, Michael W et al. (2003) Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes 52:268-76
Weinstein, Robert S; Chen, Jin-Ran; Powers, Cara C et al. (2002) Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest 109:1041-8
Weinstein, R S (2001) Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2:65-73
Borton, A J; Frederick, J P; Datto, M B et al. (2001) The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res 16:1754-64

Showing the most recent 10 out of 14 publications